Immunohistochemistry Market Research Report Information By Product (Antibodies (Primary antibodies, and Secondary antibodies), Reagents (Histological Stains, Blocking Sera), Equipment (Slide-staining Systems, Tissue Processing Systems, Slide Scanners) By Application (Diagnostic applications (Cancer, Infectious diseases, Autoimmune diseases) By End user (Hospitals & Diagnostic Laboratories, Academic & Research Institutes), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Global Immunohistochemistry Market Overview

The Immunohistochemistry Market Size was valued at USD 3 Billion in 2022. The Immunohistochemistry market industry is projected to grow from USD 3.24 Billion in 2023 to USD 5.99 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.00% during the forecast period (2024 - 2032). Companion diagnostics' increasing importance and the use of digital pathology are the key market drivers boosting the expansion of the market.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Immunohistochemistry Market Trends

• Growing digital pathology adoption is driving the market growth

Market CAGR for Immunohistochemistry is being driven by the rising adoption of digital pathology. A laboratory technique called immunohistochemistry (IHC) uses antibodies to detect particular antigens in a tissue sample. Typically, the antibodies attach themselves to a fluorescent dye or an enzyme, allowing scientists to view the antigen under a microscope. IHC is frequently used to identify the various forms of chronic illnesses, including cancer. In contrast to traditional enzyme staining methods, which are limited in their ability to recognize certain proteins, enzymes, and tissue structures, immunohistochemistry (IHC) uses particular antigen-antibody reactions.

Additionally, the continued trend of automation of diagnostic laboratory operations across major healthcare markets has led to an increase in the use of digital pathology systems by healthcare practitioners worldwide. In order to eliminate the need for physical slides and to facilitate the efficient collaboration of pathologists and researchers, traditional IHC staining is combined with digital imaging and analysis tools in digital immunohistochemistry (IHC). This makes it possible to transform stained tissue slides into electronically stored, retrievable, and analyzed images. Digital pathology application in IHC has several benefits: it does away with the need for handling and storing physical slides; it makes it easier for pathologists to collaborate remotely for case sharing and second opinions; it makes objective and standardized quantitative stain analysis possible; and it makes it possible to archive and integrate digital images with other data for thorough analysis and research.

Assays and tests, referred to as companion diagnostics, are designed to support medical professionals in treating patients by helping them determine which course of action is best for them, depending on their optimal response to therapy. Through the swift and economical production of safer medications with improved therapeutic efficacy, the co-creation of companion diagnostics and therapeutic products holds the potential to drastically change the drug development process and commercialize drug candidates. Companion diagnostics has a promising future due to the rising need for safer medications and expensive specialized therapies. The expanding significance of companion diagnostics is also creating potential prospects for the IHC market as well as the diagnostics segment.

For instance, For in vitro diagnostic medical devices, the European Parliament and Council of the European Union have released Regulation (EU) 2017/746. The current In Vitro Diagnostic Devices Directive (IVDD) 98/79/EC will be replaced by this resolution, and businesses will have five years to adapt to the more complicated and demanding new rules. Thus, result in driving the Immunohistochemistry market revenue.

Immunohistochemistry Market Segment Insights

Immunohistochemistry Product Insights

The Immunohistochemistry market segmentation, based on Product, includes Antibodies (Primary antibodies and Secondary antibodies), Reagents (Histological Stains, Blocking Sera and Reagents, Chromogenic Substrates, Fixation Reagents, Organic Solvents, Proteolytic Enzymes, Diluents, and Other Reagents), Equipment (Slide-staining Systems, Tissue Processing Systems, Slide Scanners, and Other Equipment), and Kits (IHC Kits for Human tissue, and IHC Kits for Animal tissue). In 2023, the Antibodies segment dominated the market. The tremendous improvements in product quality, sensitivity, and specificity for IHC applications that have resulted from these developments in antibody creation and manufacturing techniques should be credited for the Antibodies product segment's large market share.

Immunohistochemistry Application Insights

The Immunohistochemistry market segmentation, based on Application, includes Diagnostic applications (Cancer, Infectious diseases, Autoimmune diseases, Nephrological diseases, Neurological diseases, and other diseases), Research applications (Drug development and Testing and Other research applications), and Forensic applications. In 2023, the Diagnostic applications category generated the most income. The rising incidence of chronic diseases like cancer, neurological disorders, and autoimmune ailments, which has also increased demand for IHC diagnostic applications, is largely responsible for this segment's growth.

Immunohistochemistry End User Insights

The Immunohistochemistry market segmentation, based on End user, includes Hospitals & Diagnostic Laboratories, Academic & Research Institutes, and other end users (CROs, pharma & biopharma companies, and forensic laboratories). In 2023, The Hospitals & Diagnostic Laboratories segment dominated the market. A large increase in the volume of diagnostic testing carried out in hospitals and diagnostic labs due to the increasing prevalence of diseases like cancer, autoimmune conditions, and infectious diseases; factors such as the increasing trend of establishing in-house diagnostic facilities in hospitals to provide time-limited and affordable patient services; and the availability of reimbursement.

Figure 1:  Immunohistochemistry Market, by End User, 2023 & 2032 (USD Billion)

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Immunohistochemistry Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Immunohistochemistry market area will dominate this market because of elements like the high rate of cancer and other chronic diseases in the area, the existence of important figures, and the well-established healthcare infrastructure.

Further, the major countries studied in the market report are China, Japan, India, Australia, South Korea, Germany, France, the UK, and Italy.

Figure 2:  Immunohistochemistry Market Share By Region 2023 (USD Billion)

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Europe Immunohistochemistry market has the second-largest portion of the market. This is linked to an increase in the region's cases of chronic diseases. Further, the German Immunohistochemistry market held the largest market share, and the UK Immunohistochemistry market was the European market with the quickest rate of growth.

The Asia-Pacific Immunohistochemistry Market is anticipated to expand between 2024 and 2032 at the quickest CAGR. The high prevalence of chronic illnesses and the population's quick aging are two further elements propelling the Asia-Pacific Immunohistochemistry Industry's expansion. Moreover, China’s Immunohistochemistry market held the largest market share, and the Indian Immunohistochemistry market was the Asia-Pacific region's fastest-growing market.

Immunohistochemistry Key Market Players & Competitive Insights

Leading market players are putting a lot of money into R&D to expand their product lines, which will help the immunohistochemistry market to keep growing. Additionally, market players are engaging in a range of calculated initiatives to increase their worldwide presence, with important market developments involving the introduction of new products, contracts, M&A transactions, increased investment, and cooperation with other enterprises. To grow and endure in an increasingly cutthroat and dynamic market, the Immunohistochemistry industry must provide reasonably priced goods.

Manufacturing locally is one of the primary business techniques used by manufacturers to cut operational costs in the Immunohistochemistry industry to help customers and expand the market segment. In recent years, the Immunohistochemistry industry has provided some of the biggest benefits to medicine. Major players in the Immunohistochemistry market, including Bio-Rad Laboratories Inc. (US), Eagle Biosciences Inc. (US), Danaher Corporation (US), Agilent Technologies Inc. (US), Merck KGAA (Germany), F. Hoffmann-LA-Roche AG (Switzerland), and Biocare Medical LLC. (US), and others are engaging in research and development activities in an effort to boost market demand.

Danaher Corporation is an internationally diversified American corporation. The company is based in Washington, D.C., and creates, produces, and sells goods and services for the commercial, industrial, and medical sectors. In the past, it has made an effort to keep a very low public image and has mostly expanded through acquisitions. Kaizen is a lean manufacturing strategy from Japan that emphasizes continual improvement and waste elimination. Danaher was one of the first corporations in North America to adopt this methodology. In August 2023, Danaher declared that it had finalized an agreement to buy Abcam for about $5.7 billion, payable in cash at $24 per share.

Key Companies in the Immunohistochemistry market include

• Hoffmann-LA-Roche AG (Switzerland)


• Danaher Corporation (US)


• Agilent Technologies Inc. (US)


• Merck KGAA (Germany)


• Bio-Rad Laboratories Inc. (US)


• Eagle Biosciences Inc. (US)


• Biocare Medical LLC. (US)


• Elabscience Biotechnology Inc. (China)


• Bio-Genex Laboratories (US)


• Diagnostic Biosystem (US)


• Histo-Line Laboratories (Italy)


• Rockland Immunochemicals Inc. (US)


• Genemed Biotechnologies Inc. (US)


• Candoor Bioscience GMBH (Germany)


• Bio-Techne Corporation (US)


• Abcam PLC (UK)


• Becton, Dickinson and Company (US)


• Perkinelmer Inc. (US)


• Takara Bio, Inc. (Japan)


• Thermo Fisher Scientific Inc. (US)


• PHC Holdings Corporation (Japan)


• Cell Signaling Technology Inc. (US)


• Bio SB Inc. (US)


• Miltenyi Biotech (Germany)


• Sakura finetek Japan Co., Ltd. (Japan)


• Enzo Biochem, Inc. (US)


• Origene Technologies Inc. (US).

Immunohistochemistry Industry Developments

February 2023: IDH1 R132H (MRQ-67) Rabbit Monoclonal Antibody and ATRX Rabbit Polyclonal Antibody were introduced by F. Hoffman-La Roche AG (Switzerland) to be used in the BenchMark family of instruments for brain cancer detection.

April 2023: BOND MMR Antibody Panel for colorectal cancer detection was approved by the FDA by Danaher Corporation (US), a subsidiary of Leica Biosystems.

November 2022: Cell IDx, Inc., an immunodiagnostic business that provides chromogenic and fluorescent multiplex IHC biomarker profiling solutions, was acquired by Danaher Corporation (US), a subsidiary of Leica Biosystems Nussloch GmbH.

Immunohistochemistry Market Segmentation

Immunohistochemistry Product Outlook

• Antibodies
  
  
  
  • Primary antibodies
  
  
  • Secondary antibodies
  
  
  
  


• Reagents
  
  
  
  • Histological Stains
  
  
  • Blocking Sera and Reagents
  
  
  • Chromogenic Substrates
  
  
  • Fixation Reagents
  
  
  • Organic Solvents
  
  
  • Proteolytic Enzymes
  
  
  • Diluents
  
  
  • Other Reagents (antigen retrieval solutions, stabilizers, controls, and mounting solutions)
  
  
  
  


• Equipment
  
  
  
  • Slide-staining Systems
  
  
  • Tissue Processing Systems
  
  
  • Slide Scanners
  
  
  • Other Equipment (automated cover slippers, visualization equipment, microtomes, paraffin dispensers, slide labelers, and tissue microarrays)
  
  
  
  


• Kits
  
  
  
  • IHC Kits for Human tissue
  
  
  • IHC Kits for Animal tissue
  
  
  
  

Immunohistochemistry Application Outlook

• Diagnostic applications
  
  
  
  • Cancer
  
  
  • Infectious diseases
  
  
  • Autoimmune diseases
  
  
  • Nephrological diseases
  
  
  • Neurological diseases
  
  
  • Other diseases (ophthalmic, cardiovascular, dermatological, and dental diseases)
  
  
  
  


• Research applications
  
  
  
  • Drug Development and Testing
  
  
  • Other research applications (stem cell research and developmental biology)
  
  
  
  


• Forensic applications

Immunohistochemistry End user Outlook

• Hospitals & Diagnostic Laboratories


• Academic & Research Institutes


• Other end users (CROs, pharma & biopharma companies, and forensic laboratories)

Immunohistochemistry Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America